$0.81
−1.02%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$0.85
From 52W high−61.49%
Volume72008.00
Market cap$26.25M
P/E (TTM)—
P/S (TTM)1.4x
Div yield—
Key dataNov 4, 2026
Open
$0.85
From 52W high
−61.49%
Volume
72008.00
Market cap
$26.25M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.7x
P/E (TTM)
—
RSI (14)
38.7
MomentumView details →
1D Return
−1.02%
YTD Return
−23.43%
SummaryUpdated Jun 1, 2026
Celularity Inc. (NASDAQ:CELU) is a clinical-stage biotechnology company founded in 2016 and headquartered in Florham Park, New Jersey. The company went public in August 2019 and specializes in developing innovative cell therapies derived from placental tissue. Celularity operates at the intersection of regenerative medicine and immunotherapy, focusing on creating "off-the-shelf" allogeneic cell treatments that can be used across multiple patients without the need for personalized manufacturing. The company has evolved from its initial focus on placental-derived therapies to encompass a broader portfolio including cell banking services and commercialized wound care products.
Similar companies
Latest newsMore news →
Celularity announced that NASDAQ, INC. confirmed it had regained compliance with Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the U.S. Securities and Exchange Commission.13d agoCelularity highlighted Fontaine Vitale as a strategic partner ahead of Fontaine Vitale's planned Q1 2027 opening in Bali, creating potential new revenue opportunities in Asia-Pacific regenerative medicine.35d agoCelularity Inc. appointed Naveen Jain to its Board of Directors, succeeding Diane Parks, who resigned.36d ago